It is plausible that existing cardiovascular therapeutics utilized to treat associated risk factors or recommended lifestyle changes may directly alter MMP-12 levels and/or activity, and therefore be effective for the treatment of AAAs. This evidence concerns the gene MMP12 and achalasia-alacrima syndrome.